Beth Israel Deaconess Medical Center

The Institute for Protein Innovation launches

Friday, May 12, 2017

A team of scientists from the Massachusetts biomedical community launched a new research institute to expand protein science and enhance drug discovery. Backed by a unique and collaborative combination of public investment and academic philanthropy, The Institute for Protein Innovation (IPI) brings together leaders in academic research, biotechnology, pharmaceuticals and biomedical investing to seek new therapies for currently intractable diseases. 

[Read More]

NIH expands investment in HIV cure research

Tuesday, July 19, 2016

The NIH has awarded approximately $30 million in annual funding over the next five years to six research collaborations working to advance basic medical science toward an HIV cure. The awards comprise the second iteration of the Martin Delaney Collaboratory: Towards an HIV-1 Cure program and are a part of President Barack Obama’s pledge to invest in HIV cure research. The research program is supported by the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute on Drug Abuse, the National Institute of Mental Health and the National Institute of Neurological Disorders and Stroke, all part of the NIH.

[Read More]

Genocea releases positive results for genital herpes treatment GEN-003

Tuesday, April 5, 2016

Genocea Biosciences, a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive 12 month efficacy data from its phase II dose optimization trial evaluating GEN-003 for the treatment of genital herpes. GEN-003 demonstrated sustained and statistically significant reductions compared to baseline in the rate of viral shedding 12 months after dosing across multiple dose groups as well as sustained efficacy at multiple dose levels across secondary endpoints measuring the impact on clinical disease. GEN-003 was safe and well-tolerated by patients, with no serious adverse events related to the vaccine in the trial.

[Read More]

Apple to launch new software framework CareKit

Thursday, March 24, 2016

Apple is launching CareKit, a new software framework designed to help developers enable people to actively manage their own medical conditions. iPhone apps using CareKit make it easier for individuals to keep track of care plans and monitor symptoms and medication; providing insights that help people better understand their own health. With the ability to share information with doctors, nurses or family members, CareKit apps help people take a more active role in their health.

[Read More]

MLSC, COBTH, UMass Med launch web portal to promote collaboration

Wednesday, June 17, 2015

The Massachusetts Life Sciences Center (MLSC) partnered with the Conference of Boston Teaching Hospitals (COBTH) and the University of Massachusetts Memorial Medical Center to the launch the Massachusetts Clinical Innovation Gateway. The new web portal will allow life sciences companies from around the world to seek opportunities to partner with Massachusetts academic medical centers (AMCs) on research and clinical initiatives.

[Read More]

Synthetic Biologics fills irritable bowel syndrome Clinical Advisory Board

Thursday, October 16, 2014

Synthetic Biologics, a biotechnology company developing novel anti-infective biologics and drugs targeting specific pathogens that cause serious infections and diseases, has expanded its Clinical Advisory Board (CAB) created to support development of SYN-010, the company’s statin-class candidate intended to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS).

[Read More]